ZOGENIX, INC. (NASDAQ:ZGNX) Files An 8-K Results of Operations and Financial Condition

Item2.02Results of Operations and Financial Condition.

On January9, 2017, Zogenix, Inc. (the Company or Zogenix)
announced that its preliminary unaudited cash and cash
equivalents as of December31, 2016 were approximately
$91.6million.

The preliminary unaudited cash position discussed above is
subject to the completion of financial closing procedures and
other developments that may arise between now and the time the
financial results for the fourth quarter are finalized, as well
as the completion of the audit of the 2016 financial statements.
Therefore, actual results may differ materially from these
estimates. In addition, the above estimates do not present all
information necessary for an understanding of Zogenixs financial
condition as of December31, 2016.

In accordance with General Instruction B.2 of Form 8-K, the
information in Item2.02 of this Current Report on Form 8-K shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended (the Securities Act), or the Exchange Act,
whether made before or after the date hereof, except as expressly
set forth by specific reference in such filing to this Current
Report on Form 8-K.

Item7.01Regulation FD Disclosure.

Beginning on January9, 2017, representatives of Zogenix will be
attending meetings with investors, analysts and other parties in
connection with the J.P. Morgan 34th Annual Healthcare Conference
in San Francisco, California. During these meetings, Zogenix will
present the slides attached as Exhibit 99.1 to this Current
Report on Form 8-K, which is incorporated herein by reference.

The information in this Item7.01, including Exhibit 99.1, is
being furnished to Item7.01 and shall not be deemed filed for
purposes of Section18 of the Exchange Act or otherwise subject to
the liabilities of that section, and it shall not be deemed
incorporated by reference in any filing under the Securities Act,
whether made before or after the date hereof, except as expressly
set forth by specific reference in such filing to this item of
this report.

***

Zogenix cautions you that statements included in this report that
are not a description of historical facts are forward-looking
statements. Words such as believes, anticipates, plans, expects,
indicates, will, intends, potential, suggests, assuming and
similar expressions are intended to identify forward-looking
statements. These statements are based on the Companys current
beliefs and expectations. These forward-looking statements
include statements regarding Zogenixs cash position as of
December31, 2016, the potential commercialization of ZX008; the
timing of top-line results from the Phase 3 clinical trial of
ZX008 in Dravet syndrome and other 2017 milestones; and the
timing of any submission of a new drug application to the U.S.
Food and Drug Administration or comparable market authorization
filing in Europe. The inclusion of forward-looking statements
should not be regarded as a representation by Zogenix that any of
its plans will be achieved. Actual results may differ from those
set forth in this report due to the risks and uncertainties
inherent in Zogenixs business, including, without limitation:
risks related to changes in estimated financial amounts based on
the completion of financial closing procedures and the audit of
the financial statements, the uncertainties associated with the
clinical development and regulatory approval of product
candidates such as ZX008, including potential delays in the
commencement, enrollment and completion of clinical trials; the
potential that earlier clinical trials and studies may not be
predictive of future results; Zogenixs reliance on third parties
to conduct its clinical trials, enroll patients, manufacture its
preclinical and clinical drug supplies and manufacture commercial
supplies of its drug products, if approved; unexpected adverse
side effects or inadequate therapeutic efficacy of ZX008 that
could limit approval and/or commercialization, or that could
result in recalls or product liability claims; Zogenixs ability
to fully comply with numerous federal, state and local laws and
regulatory requirements, as well as rules and regulations outside
the United States, that apply to its product development
activities; Fast Track designation may not result in an expedited
regulatory review process; the potential for distraction of
management related to the transition of management
responsibilities; and other risks described in Zogenixs filings
with the Securities and Exchange Commission. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and Zogenix undertakes no
obligation to revise or update this report to reflect events or
circumstances after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement. This caution is made under the safe harbor provisions
of Section21E of the Private Securities Litigation Reform Act of
1995.

Item9.01.Financial Statements and Exhibits.

(d) Exhibits.

About ZOGENIX, INC. (NASDAQ:ZGNX)

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.

ZOGENIX, INC. (NASDAQ:ZGNX) Recent Trading Information

ZOGENIX, INC. (NASDAQ:ZGNX) closed its last trading session down -0.05 at 12.75 with 150,101 shares trading hands.